We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · April 05, 2021

Disease-Modifying Effects of Edasalonexent in Duchenne Muscular Dystrophy

Neuromuscular Disorders


Additional Info

Disclosure statements are available on the authors' profiles:

Neuromuscular Disorders
Disease-Modifying Effects of Edasalonexent, an NF-κB Inhibitor, in Young Boys With Duchenne Muscular Dystrophy: Results of the MoveDMD Phase 2 and Open Label Extension Trial
Neuromuscul. Disord. 2021 Feb 04;[EPub Ahead of Print], RS Finkel, E Finanger, K Vandenborne, HL Sweeney, G Tennekoon, PB Shieh, R Willcocks, G Walter, WD Rooney, SC Forbes, WT Triplett, SW Yum, M Mancini, J MacDougall, A Fretzen, P Bista, A Nichols, JM Donovan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading